Mirum Reports Positive ATEBRIOZ Results In Younger Children With FOP

Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.

Mirum Pharmaceuticals reported positive Phase II trial data for Atebrioz (zilurgisertib) in paediatric FOP patients. Over 24 weeks, the drug reduced lesion volume and improved joint mobility. Mirum plans to submit an NDA expansion in 2027. The study showed a mean HO lesion volume reduction of 8.09cm³ with zilurgisertib versus a 9.14cm³ increase with placebo.

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.

Mirum Pharmaceuticals reported positive results from a pediatric study of ATEBRIOZ, showing reduced heterotopic ossification and improved joint mobility in children aged 6 to under 12 with FOP. At Week 24, lesion volume decreased by 8.09 cm³ with zilurgisertib and increased by 9.14 cm³ with placebo. The company plans to submit an sNDA in the first half of 2027 for expanded use.

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. (the “Company”)

Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study, showing ATEBRIOZ (zilurgisertib) reduced bone lesion volume in younger children with FOP. The drug showed a 14.0 cm³ improvement over placebo. Mirum plans to submit a supplemental NDA in 2027 to expand the indication. MIRM stock is up 2.51%.